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Background: Recent advances in the management of Barrett’s Esophagus (BE) have placed greater emphasis on
accurate diagnosis of BE as well as better prediction of risk for progression to esophageal adenocarcinoma (EAC).
Histological evaluation of BE is particularly challenging with significant inter-observer variability. We explored the
presence and extent of genomic instability in BE biopsy specimens as a means to add supplementary information
to the histological classification and clinical decision-making related to early disease.
Methods: We reviewed histology slides from 271 patients known to have BE. Using histological features as a guide,
we microdissected target cell populations with various histological classifications of BE (intestinal metaplasia,
“indefinite for dysplasia”, low grade dysplasia, or high grade dysplasia). DNA was extracted from microdissected
targets and analyzed for loss of heterozygosity (LOH) using a panel of 16 LOH mutational markers associated with
tumor suppressor genes at chromosomal loci 1p, 3p, 5q, 9p, 10q, 17p, 17q, 18q, 21q, 22q. The presence or absence
of mutations and the clonality of each mutation were determined for each marker.
Results: The presence and clonal expansion of LOH mutations was formulated into mutational load (ML) for each
microdissected target analyzed. ML correlated with the histological classification of microdissected targets, with
increasingly severe histology having higher ML. Three levels of mutation load (no ML, low ML, and high ML) were
defined based on the population of microdissected targets histologically classified as intestinal metaplasia. All
microdissected targets with dysplasia had mutations, with a high ML consistently present in high grade dysplasia
targets. Microdissected targets histologically classified as intestinal metaplasia or “indefinite for dysplasia” spanned a
range of no, low, and high ML.
Conclusions: The results of this study reinforce the association of genomic instability with disease progression in
BE. The presence and extent (clonality) of genomic instability, as assessed by mutational load, may assist histology
in defining early stages of BE that are potentially at greater risk for disease progression. Assessment of mutational
load using our panel of LOH mutational markers may be a useful adjunct to microscopic inspection of biopsy
specimens, and thereby, improve patient management.
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Barrett’s Esophagus (BE) is a pre-malignant condition
that is associated with increased risk of esophageal ade-
nocarcioma (EAC) [1]. EAC carries a relatively poor
prognosis, with a 5-year survival rate below 13.6% [2]. In
order to avoid progression to EAC, early intervention
has become a primary focus. During BE carcinogenesis,
genetic alterations that favor unregulated cell growth,
such as activation of oncogenes and inactivation of
tumor suppressor genes, cause morphologic changes in
esophageal tissue [1]. Various studies have firmly estab-
lished that mutational change involving tumor suppres-
sor genes occurs at the histological onset of BE [3]. The
more concerning histological categories of BE (i.e., the
various grades of dysplasia) and EAC have been closely
linked to progressive accumulation of multiple oncogene
and tumor suppressor gene mutations [3].
Histological classification of BE is essential to disease
management. Current guidelines define BE as specialized
intestinal metaplasia with goblet cells [4]. These guide-
lines recognize the following histological classifications
of BE in order of increasing severity: intestinal metapla-
sia, “indefinite for dysplasia”, low grade dysplasia (LGD),
and high grade dysplasia (HGD). HGD is associated with
greater risk of progression to EAC and, thus, warrants
clinical intervention [5-8]. Recent guidelines call for
LGD to be confirmed by a second pathologist prior to
clinical intervention [4].
Although microscopic examination can readily identify
BE and EAC, the various grades of dysplasia can be
difficult to diagnose. The histological classification of
dysplasia involves two especially challenging aspects:
i) discriminating reactive epithelial atypia secondary to
inflammation from the presence of true dysplasia; and,
ii) distinguishing between the two different grades of
dysplasia (LGD, HGD) [9-13]. Various guidelines for
microscopic interpretation address these aspects, but,
because of difficulties in defining precise thresholds of
cumulative atypia, different pathologists may interpret the
guidelines in different ways. In addition, a histological
classification of “indefinite for dysplasia” is, at times,
provided when cellular atypia is observed but does not
clearly indicate dysplasia.
Consistently, many studies have shown inter-observer
variability in the histological classification of Barrett’s
dysplasia [9-13]. Such variability occurs among expert
gastrointestinal (GI) pathologists, as well as those with-
out GI specialization. In a recent study, up to 85% of
patients who had LGD were re-diagnosed as having
non-dysplastic BE or “indefinite for dysplasia” following
pathology review [13]. The most pronounced variability
in classification occurs around LGD, although variability
can also be encountered in HGD. Because variability
occurs even among expert pathologists, a substantialpossibility for under- or over-diagnosis of dysplasia and
its associated grades remains, thus complicating the de-
cision of whether or not to perform treatment or alter
the surveillance interval of the patient. The uncertainty
in the diagnosis of histological dysplasia can limit strati-
fication for the risk of EAC and make it difficult for a
treating physician to know if a particular patient’s BE is
at risk for progression.
A variety of endoscopic techniques exist for treating
BE, including endoscopic mucosal resection, radiofre-
quency ablation (RFA), cryoablation, endoscopic sub-
mucosal dissection, and photodynamic therapy. Because
these procedures are generally well tolerated, they are
now routinely applied. Current American Gastroentero-
logical Association (AGA) guidelines endorse endo-
scopic therapies in managing patients with high-grade
dysplasia and “confirmed” LGD [1,4]; “confirmed” LGD
is defined as diagnosis of histological LGD by at least
two pathologists. Due to difficulties in histopathological
diagnosis, debate continues regarding when endoscopic
therapies should be performed in BE.
At present, there are no observable microscopic fea-
tures of metaplasia that can determine if BE is likely to
undergo disease progression to cancer or remain stable.
The limited ability of histological features alone to iden-
tify those intestinal metaplasia cases likely to progress
has led many to consider ablation and other interven-
tions at the earliest stage of BE disease. This increased
use of ablation has raised concerns over the associated
healthcare economic burden [14,15]. Thus, supplemen-
tary diagnostic modalities that help to better characterize
the early stages of disease would be a valuable addition
to personalizing patient treatment and controlling these
healthcare costs.
We aimed to better understand the relationship be-
tween histological changes in BE and the presence and
extent of mutation acquisition. Previous work using
microdissection-guided broad panel profiling for loss of
heterozygosity (LOH) mutations in proximity to tumor
suppressor genes has shown clinical utility for a variety
of cancer applications [16-25]. We employed this
method to characterize multiple histological sites within
esophageal biopsy specimens from patients with BE.
Areas of tissue with various histological classifications
were tested for the presence and clonality of LOH
across a panel of relevant genomic loci in order to
characterize the overall LOH mutational load next to
tumor suppressor genes. We hypothesized that increas-
ing mutational load would correlate with increasingly
severe histological classifications of BE. We show that
an analytically objective and reproducible measure of
the presence and extent of genomic instability, as
assessed by mutational load, can assist histology in the
characterization of BE.
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Study cohort
We microscopically reviewed standard histological sec-
tions (4 μm thick) of archival, formalin-fixed, paraffin-
embedded (FFPE) tissue from 271 patients histologically
known to have BE. The study protocol was Quorum
Review IRB approved (#26163) on June 8, 2011. Patients
in the study cohort had previously undergone upper GI
endoscopy and pathology review of biopsy specimens.
We selected patients with a histological classification of
intestinal metaplasia, “indefinite for dysplasia”, and vari-
ous grades of dysplasia for inclusion in the study.
Patients without evidence of BE were excluded, as were
patients with intramucosal and/or invasive carcinoma.
Microdissection
Hematoxylin and eosin (H&E) stained, FFPE slides were
used to guide microdissections of histologically classified
targets from unstained, serial FFPE slides. Multiple dis-
tinct regions were microdissected from each slide to en-
rich for cells corresponding to distinct foci (targets) of
histologically classified disease. Multiple microdissection
targets were taken according to the availability of topo-
graphically separate tissue fragments, even when these
fragments were from the same histological classification of
BE (Figure 1). 1-3 targets of BE histology were microdis-
sected from each patient’s FFPE biopsy specimen
(2X-4X, Figure 1). Separate microdissected targets of
histologically classified normal squamous epithelium (1N,
Figure 1) and epithelium containing columnar cells that
were not intestinalized (e.g., normal squamous and non-Figure 1 Representative formalin-fixed, paraffin embedded
(FFPE), hematoxylin and eosin (H&E) stained slide of Barrett’s
epithelium. Multiple re-cuts of several biopsies from the same
patient are present on the slide. Multiple histological targets were
microdissected from such slides for molecular analyses. 1N indicates
a normal, non-Barrett’s epithelial microdissected target used as a
baseline control. 2x, 3x, and 4x indicate individual microdissected
targets containing Barrett’s epithelium.Barrett’s columnar mucosa) were examined as a baseline
control for mutational markers. These targets were
microdissected from the same FFPE slides as targets
with various histological classifications of BE. Accuracy
of microdissection was confirmed by microscopic re-
view of post-microdissection stained slides.Histological classification
A histological classification for each microdissected
target was assigned based on review of the specimens
and accompanying histopathology reports from the
original microscopic review. When consensus between
pathologists was available, it was used as the histological
classification for the microdissected target. When con-
sensus was not available, we relied on the histological
classification of the expert pathologist in our group.
Microdissected targets were classified as non-Barrett’s
epithelium and Barrett’s epithelium using the following
histological classifications in order of increasing severity:
normal squamous and columnar mucosa for non-Barrett’s
epithelial microdissected targets, and intestinal metaplasia,
“indefinite for dysplasia”, LGD, and HGD for Barrett’s
epithelial microdissected targets.Detection of LOH
Using PCR and quantitative capillary electrophoresis, as
previously described [19,20], we assessed 16 LOH mar-
kers associated with common tumor suppressor genes
relevant to BE. The panel contained markers at the fol-
lowing 10 chromosomal loci (associated genes in paren-
thesis): 1p (CMM1, L-myc), 3p (VHL, HoGG1), 5q
(MCC, APC), 9p (CDKN2A), 10q (PTEN, MXI1), 17p
(TP53), 17q (NME1), 18q (DCC), 21q (TFF1 and PSEN2)
and 22q (NF2) [19,20,26-28]. These markers have been
analytically validated to detect LOH and were selected
post-qualification studies using surgically resected EAC
specimens microdissected at sites of intestinal metapla-
sia, dysplasia, and EAC, with histological classification at
each site representing consensus of four GI pathologists.
The results of such studies were used to define this
smaller, more relevant panel of genomic loci, which
includes LOH markers that had mutations in at least
20% of the surgical EAC specimens.
Before LOH was determined for each marker, DNA
from all patients was examined to ensure it was ad-
equate for PCR amplification using quantitative PCR
(qPCR) results for housekeeping genes. This was per-
formed on both lesional microdissection samples as well
as non-neoplastic internal controls (normal appearing
squamous and columnar mucosa and/or stromal tissue
targets) all subject to equivalent formalin fixation and
histological processing. PCR amplification and LOH ana-
lysis using quantitative capillary electrophoresis methods
Table 1 Demographics of patients included in study
Age (years) Male Female Total
< 40 8 2 10
40-50 31 13 44
50-60 54 26 80
60-70 59 14 73
70-80 33 10 43
≥ 80 14 7 21
Total 199 72 271
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with adequate qPCR results.
To determine if each LOH analysis was assessable in
each patient, the informativeness (heterozygosity) of
each LOH marker in normal, non-Barretts tissue from
each patient (1N, Figure 1) was evaluated to determine if
the microsatellite repeats were homo- or heterozygous
in length. In addition, preliminary studies characterized
normal variability for each pairing of allele lengths
examined for LOH in order to account for differing nu-
cleic acid amplifications related to differences in allele
length during PCR amplification. Normal squamous,
non-Barrett’s epithelial microdissected targets were used
to characterize this variability.
LOH was determined present when there was a degree
of allelic imbalance that was equal to or beyond two
standard deviations above the average difference in allele
peak heights for DNA in non-neoplastic normal micro-
dissection targets (1N, Figure 1). The degree (clonality)
of LOH was quantitatively estimated using the ratio of
allele peak heights, which is proportional to the amount
of LOH mutated DNA (and cells) present in the sample
[19,20]. Each microdissected target with LOH was tested
in duplicate or triplicate to ensure reproducibility. LOH
mutations were defined as high clonality when >75% of the
DNA had LOH mutation and low clonality when 50-75%
of the DNA had LOH mutation. When <50% of the DNA
was mutated, no mutations were reported due to the ana-
lytical limit of detection of the assay, which was 50% for
each LOH.
Analysis and determination of mutational load
For each microdissected target, we determined the pres-
ence of each LOH mutation at a given genomic loci and
whether or not each LOH mutation was low or high
clonality (i.e. whether or not 50-75% of the DNA con-
tained LOH or >75% of the DNA contained LOH). Pro-
portional odds logistic regression (POLR) was used to
assign a numerical value to low clonality mutations and
to high clonality mutations. In performing POLR, vari-
ous histological classifications of epithelia were grouped
together (e.g. non-BE epithelium vs. intestinal metaplasia
vs. LGD vs. HGD, including or excluding “indefinite for
dysplasia” microdissected targets, or all non-dysplastic
vs dysplastic, etc.) to determine the impact on the calcu-
lated values. Proportional values were also evaluated
using FAL (fractional allelic loss), which is analysis for
the proportions of low and high clonality mutations to
the number of informative markers. All results from
various analyses consistently determined a proportional
value of 0.5 for low clonality mutations and 1 for high
clonality mutations. These numerical values for low
clonality and high clonality mutations were added to-
gether for all loci containing LOH in a microdissectedtarget. The resulting cumulative value was defined as the
mutation load (ML) for that microdissected target.
We examined the correlation between histological
class and mutational load using Spearman rank correl-
ation and calculated frequency distributions for each
histological class within the study population. Levels of
mutational load (ML) were established based on the fre-
quency with which a particular level of ML was observed
in microdissected targets histologically classified as in-
testinal metaplasia. The no ML level consisted only of
intestinal metaplasia microdissected targets that lacked
detectable mutations. The high ML level was defined as
the level that captured 5% of intestinal metaplasia micro-
dissected targets that had the highest level of ML. How-
ever, because ML was defined at discrete levels, only 4%
of intestinal metaplasia microdissected targets were
included by this cutoff. The low ML level included all in-
testinal metaplasia microdissected targets that had muta-
tions but had an ML below the high ML cutoff. We used
these levels of ML to evaluate the mutational load in
other histological classifications. The frequency of muta-
tions in various genomic loci of each microdissected tar-
get was also determined for each histological class.
Results
LOH mutational analysis
Esophageal biopsies were examined for LOH mutational
profiles adjacent to tumor suppressor genes. Each FFPE
biopsy slide was microdissected at multiple target sites
as guided by histologically observed cellular morphology
(Figure 1). Microdissections of distinct targets were
performed on patient samples with various demogra-
phics (Table 1). There were 199 males and 72 females
from which 568 distinct microdissection targets were
analyzable.
The number of LOH mutations was determined in
microdissected targets with various histological classifi-
cations. Table 2 summarizes the number of mutated
LOH loci per microdissected target averaged for all
targets across the range of histological classes examined.
The number of mutated LOH loci increased with
increasing severity of histological classification. Most LOH








Average number of low/ligh clonality mutations




Normal Squamous 82 0.1 0.1 0.0 0.1
Columnar 77 0.6 0.6 0.0 0.3
Intestinal Metaplasia 216 1.5 1.2 0.3 0.9
Indefinite for dysplasia 138 2.0 1.7 0.3 1.1
Low grade dysplasia 39 3.5 2.7 0.8 2.2
High grade dysplasia 16 4.0 1.5 2.5 3.3
Ellsworth et al. BMC Gastroenterology 2012, 12:181 Page 5 of 10
http://www.biomedcentral.com/1471-230X/12/181mutations were detected in HGD microdissected targets,
and in those HGD targets a relatively high proportion of
DNA (>75%) was found with these mutations (high
clonality). While most mutations found in HGD targets
were high clonality, mutations found in non-dysplastic
histological classifications (intestinal metaplasia, “indefin-
ite for dysplasia”) were typically low clonality. Compared
to microdissected targets with Barrett’s histology, there
were less mutations detected in targets histologically
classified as normal squamous epithelium and epithelium
containing columnar cells that were not intestinalized
(columnar, non-Barrett’s epithelium), and importantly,
there were no high clonality mutations found in these
microdissected targets (Table 2).
Mutations were observed across the entire panel of gen-
omic loci examined. Table 3 summarizes the frequency of
mutation in each genomic loci for microdissected targets
within each histological class. Microdissected targets his-
tologically classified with dysplasia had the highest fre-
quency of mutations at 17p (TP53), with mutations









N = 82 N = 77 N =216
1p CMM1, LMYC 1 (1%) 0 13 (6%)
3p VHL, OGG1 1 (1%) 4 (5%) 29 (13%
5q MCC, APC 2 (2%) 8 (10%) 43 (20%
9p CDKN2A 4 (5%) 4 (5%) 56 (26%
10q PTEN, MXI1 0 11 (14%) 54 (25%
17p TP53 1 (1%) 4 (5%) 35 (16%
17q NME1 1 (1%) 7 (9%) 21 (10%
18q DCC 1 (1%) 7 (9%) 41 (19%
21q TFF1, PSEN2 0 3 (4%) 20 (9%)
22q NF2 0 0 11 (5%)
Bold numbers indicate that at least 25% of microdissected targets tested with eachtargets, and 49/138 (36%) “indefinite for dysplasia” targets.
9p (CDKN2A) was also more frequently mutated than
other loci with 7/16 (44%) HGD targets, 20/39 (51%) LGD
targets, and 45/138 (33%) “indefinite for dysplasia” targets
displaying mutations.
Assessment of genomic instability
Mutational load (Table 2, Figure 2) for a microdissected
target represents the accumulation of clonally expanded
LOH mutations next to tumor suppressor genes. High
clonality LOH mutations were present when >75% of
the DNA from the microdissected target had an LOH
mutation, suggesting the presence of clonally expanded
cells with that LOH mutation in the microdissected tar-
get. Low clonality LOH mutations were present when
50-75% of the DNA from the microdissected target had
an LOH mutation. We used a semi-quantitative analysis
that incorporated both the presence and clonality of all
tested LOH mutations to provide an assessment of mu-
tational load for a given microdissected target. In this
system, we assigned low clonality mutations with argets by histological classifications









N = 138 N = 39 N = 16
20 (14%) 11 (28%) 5 (31%)
) 24 (17%) 20 (51%) 8 (50%)
) 25 (18%) 11 (28%) 13 (81%)
) 45 (33%) 20 (51%) 7 (44%)
) 40 (29%) 12 (31%) 2 (13%)
) 49 (36%) 27 (69%) 14 (88%)
) 33 (24%) 17 (44%) 9 (56%)
) 14 (10%) 12 (31%) 4 (25%)
18 (13%) 7 (18%) 0
3 (2%) 0 2 (13%)
histological classification had the indicated LOH mutations.
Figure 2 Mutational load (ML) in microdissected targets by histological classification. A.) There was a statistically significant correlation
between increasingly severe histological classification and increasing mutational load (corr. coef., (ρ), =0.6; p<0.0001). B.) Levels of mutational load
(no ML, low ML, high ML) were established within microdissected targets histologically diagnosed as intestinal metaplasia and then applied to
other histological classifications. NS = normal squamous epithelium; Col = columnar, non-Barrett’s epithelium; IM = intestinal metaplasia; IND =
“indefinite for dysplasia”; LGD = low grade dysplasia; HGD = high grade dysplasia; ML = mutational load.
Table 4 Frequencies of mutational load (ML) in





Level of Mutational load (ML)
No ML Low ML





Normal squamous 74 (90%) 8 (10%) 0 (0%)
Columnar 47 (61%) 30 (39%) 0 (0%)
Intestinal metaplasia 48 (22%) 159 (74%) 9 (4%)
Indefinite for dysplasia 20 (14%) 106 (77%) 12 (9%)
Low grade dysplasia 0 (0%) 22 (56%) 17 (44%)
High grade dysplasia 0 (0%) 1 (6%) 15 (94%)
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a value of 1. These numerical values for low clonality
and high clonality mutations were added together for all
loci containing LOH in a microdissected target. The
resulting cumulative value was defined as the mutation
load (ML) for that microdissected target.
The mutational load for each microdissected target
was correlated to the histological class of the target
(Figure 2). Mutational load was positively correlated to
histological classification, with the number and clonality
of mutations increasing with increasingly severe histo-
logical classification (Figure 2A). Using the frequency
with which mutational load was observed in intestinal
metaplasia we established three levels of Mutational
Load (ML) with respect to each histological classification
(Figure 2B). The first level contained microdissected tar-
gets that lacked mutations and, as such, had no detect-
able ML. The second level contained microdissected
targets with one low clonality mutation to two high
clonality mutations with a mutational load greater than
0 but less than or equal to 2 and was defined as having
low ML. The third level contained microdissected tar-
gets with greater than two high clonality mutations with
a mutational load greater than 2 and was defined as hav-
ing high ML.
Table 4 summarizes the proportion of microdissected
targets for each level of mutational load in each histo-
logical class. The majority of histological microdissected
targets with normal squamous epithelium and epithe-
lium containing columnar cells that were not intestina-
lized (90% of normal squamous epithelial microdissected
targets and 61% of columnar, non-Barrett’s epithelial tar-
gets) had no detectable ML (Table 4). Of the proportion
of squamous and columnar microdissected targets that
had mutations, all were low clonality mutations falling
into levels of low ML (Table 2). 22% of histologicallydiagnosed intestinal metaplasia microdissected targets
and 14% of “indefinite for dysplasia” microdissected tar-
gets had no ML, while the remaining proportion of
intestinal metaplasia and “indefinite for dysplasia”
microdissected targets had mutations with varying
degrees of ML. All microdissected targets histologically
classified as HGD and LGD had mutations with all
targets falling into the low ML or high ML levels. All
but one HGD microdissected target was characterized
having high ML. Comparatively, only 4% of intestinal
metaplasia and 9% of “indefinite for dysplasia” microdis-
sected targets were characterized as having a high ML.
Discussion
Accumulation of genomic instability within and next to
oncogenes and tumor suppressor genes is associated
with unregulated cell growth that can result in expan-
sion of clonal cell populations and, ultimately, progres-
sion to cancer [3,29]. In this study, we surveyed the
presence and extent of genomic instability by assessing
the presence and clonality of LOH mutations adjacent to
tumor suppressor genes in microdissected tissue targets
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and extent of LOH mutations in tissue was correlated to
its histological class. Microdissected targets, guided by
morphological features, were taken at multiple sites, as
available, in biopsy specimens. The overall number and
extent of mutations were formulated into a mutational
load that increased in correlation with increasingly se-
vere histological classification. This correlation is con-
sistent with the association of genomic instability with
clonal expansion of cells and disease progression in BE.
BE microdissected targets with a histological classifica-
tion of intestinal metaplasia were used to define three
levels of Mutational Load (ML) with respect to each
histological class: no ML, low ML and high ML
(Figure 2B, Table 3). Levels of mutational load in tumor
suppressor genes were established with respect to speci-
mens histologically classified with intestinal metaplasia
because i) the presence of intestinal metaplasia can be
relatively reliably diagnosed [10,12]; and, ii) intestinal
metaplasia is more prevalent in the clinical population
than more severe histological classes of BE [30]. There-
fore, defining levels of mutational load with respect to
intestinal metaplasia makes the levels most relevant to
the most frequent and reliable histology found in
patients with BE. Microdissected targets with no ML
were found in non-dysplastic histological classifications.
Microdissected targets with low ML had relatively low
levels of LOH mutational accumulation without evi-
dence of clonal expansion of mutated cells. Microdis-
sected targets with high ML had relatively high levels of
LOH mutational load and clonal expansion of cells with
these mutations. High ML was consistently found in
higher levels of histological dysplasia; however, high ML
was also seen in some cases with less severe histological
classifications, such as intestinal metaplasia.
Specimens histologically classified as intestinal meta-
plasia and “indefinite for dysplasia” spanned a similar
spectrum of LOH mutational load (no ML through high
ML). We found that 78% of intestinal metaplasia micro-
dissected targets had detectable mutations, despite the
absence of morphological changes indicative of dyspla-
sia. These results are consistent with a large body of
work suggesting that DNA alterations in BE precede the
overt morphological development of dysplasia [3,29]. In-
flammatory responses can produce cellular changes that
overlap those seen in true, confirmed histological dyspla-
sia making differentiation of reactive atypia from true
dysplasia difficult to determine. “Indefinite for dysplasia”
microdissected targets tended to have higher mutation
load than those with intestinal metaplasia, with muta-
tions detected in 86% of microdissected targets (Table 4).
Since these microdissected targets were histologically
indefinite, some may, in fact, have more advanced histo-
logical disease than others. As with intestinal metaplasia,some “indefinite for dysplasia” microdissected targets
may have mutations that precede morphological changes
consistent with dysplasia. Therefore, mutational load
analysis may provide additional information to aid in
clinical diagnosis and management when such micro-
scopic changes have yet to occur or are indefinite.
Lack of mutations (no ML) was observed in microdis-
sected targets histologically classified as normal squa-
mous epithelium and epithelium containing columnar
cells that were not intestinalized (90% of normal squa-
mous epithelial targets; 61% of columnar, non-Barrett’s
epithelial targets) and in some of those classified with in-
testinal metaplasia (22%) and “indefinite for dysplasia”
(14%) (Table 4). This lack of mutations (no ML) was not
detected in any microdissected targets with histological
dysplasia. In our previous experience across other organ
groups using a similar LOH panel to examine mutations
located near tumor suppressor genes, cell populations
that lacked detectable LOH mutations were strongly cor-
related with benign, reactive processes [18,21,31,32]. Al-
though gene panels employed in this study and previous
ones are not a complete examination of the entire gen-
ome, the absence of clonally expanded LOH mutations
next to the large number of tumor suppressor genes sur-
veyed in our panel is strong evidence that the microdis-
sected targets examined did not have extensive genomic
instability. Therefore, microdissected targets that lack
mutational load (no ML) are likely in the very early
stages of neoplastic development or are morphologically
displaying benign, reactive processes.
Microdissected targets that displayed low ML and
were histologically classified as normal squamous epithe-
lium and epithelium containing non-intestinalized col-
umnar cells (10% of normal squamous epithelial targets;
39% of columnar, non-Barrett’s epithelial targets) could
represent actual mutations within histologically normal
appearing mucosa or detection of mutated DNA from
adjacent cells or intercellular fluids. The squamous and
columnar mucosal targets were microdissected from the
same FFPE biopsy slides as those histologically diag-
nosed with BE, making it possible that mutations from
the adjacent Barrett’s epithelium or intercellular fluids
were detected. The mutational load in these squamous
and columnar epithelial microdissected targets could
also represent chromosomal aberrations that have yet to
become morphologically visible by histology. The inabil-
ity to assess the baseline mutational load in normal epi-
thelium from a patient who lacks BE is a limitation of
this type of study.
HGD is considered a severe premalignant event that
requires clinical intervention, because it is associated
with greater risk of progression to EAC [5-8]. In our
study, applying cutoffs derived from intestinal metaplasia
histological targets classified all but one HGD target as
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levels of genomic instability with more severe histo-
logical classifications of BE and is in line with the con-
cept that patients with high ML may also be at greater
risk of progression to EAC. Consistently, the presence of
three or more DNA abnormalities in patients has been
associated with a greater risk of progression towards
cancer [33]. High ML may, therefore, provide support
for associated interventions, even when histological clas-
sification of BE may be less than severe dysplasia (intes-
tinal metaplasia, “indefinite for dysplasia”, LGD). High
ML in less severe histological classifications of BE may
be indicative of impending morphological changes that
have yet to become histologically visible.
Our study is consistent with others that have described
LOH mutations adjacent to TP53 and CDKN2A tumor
suppressor genes, which together have been associated
with greater risk of BE progression to cancer [33-35].
When LOH mutations next to these genes have been
analyzed in combination with additional DNA molecular
markers for genomic instability, the risk of progression
increases by over 4 fold at 10 years (relative risk of 38.7)
[33]. Similar to these studies, we examined the muta-
tional load in cell populations using a diverse DNA mo-
lecular panel to assess genomic instability. LOH adjacent
to TP53 and CDKN2A tumor suppressor genes were
included in our panel and were found most frequently in
microdissected targets with dysplasia (Table 3). Also
included in our panel were 12 additional LOH markers
next to other tumor suppressor genes relevant to BE and
EAC [19,20,26-28]. Mutations were found in every one
of the LOH markers in our panel (Table 3). Further-
more, the clonality of each LOH mutation was also
assessed (Table 2). Increasing sizes of clones with gen-
omic instability have been associated with increased risk
of progression to EAC [35]. Consistently, the mutational
load, which incorporates both the number and clonality
of mutations, increased with increasingly severe histo-
logical class of BE, suggesting that mutational load is a
relevant measure of genetic damage that can provide
additional, objective information to the existing histo-
logical classification.
In addition to enhancing histological classification, this
type of mutational profiling may also facilitate patient
monitoring using sequential biopsies taken over varying
periods of time prior to determining if ablation is
needed. Furthermore, it can provide objective molecular
information with respect to the success of ablation [36].
As with other forms of neoplasia, distinct clones of dis-
ease acquire distinct mutations, and a new clone is un-
likely to have the same mutational profile as an existing
clone. Incomplete elimination of the original clonal cell
populations would be reflected in the same mutations
persisting after ablation. In contrast, when the mutationalprofile in follow up biopsies differs from that of the initial
biopsy, new clones of cells, as identified by different
mutations, have likely evolved. When there is no evidence
of mutations in follow up biopsies, complete eradication
of atypical clones has likely been achieved.
A chief limitation in this study and all studies of BE is
the variability associated with histological classification
and the resulting lack of standardized histological classes
for comparison to molecular results. Another limitation
of this study concerns specimen type. Histology slides
from biopsies are valuable specimens for studies such as
this one, as they represent “real-world” specimens. How-
ever, biopsies are subject to sampling variation because,
although current guidelines call for four-quadrant biop-
sies every 1cm across the region of dysplastic BE [4], in
clinical practice, more limited sampling often occurs.
Conclusions
The results of this study support the combined use of
histological classification and mutational analysis to bet-
ter evaluate BE. We demonstrate that various levels of
mutational load (no ML, low ML, and high ML) adja-
cent to tumor suppressor genes exist within each histo-
logical classification (intestinal metaplasia, “indefinite for
dysplasia”, LGD, HGD). HGD consistently has high ML,
while other less severe histological classifications have a
heterogeneous range of ML, spanning from no ML
through high ML. According to the American Gastro-
enterological Association technical review of BE man-
agement, when initial biopsy specimens histologically
show no dysplasia, indefinite dysplasia, or LGD, risk
stratification for BE progression to EAC may be deter-
mined from collective clinical information, including the
combined use of histological assessment and molecular
biomarker information, if/when appropriate [1]. Assess-
ment of biopsy specimens for levels of mutational load
using our panel of molecular markers provides a relevant,
objective, and reproducible measure of the presence and
extent of mutational change that may provide an additional,
quantitative dimension to histopathology for determining
appropriate patient management.
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